CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
CVRx, Inc. (CVRX)
Company Research
Source: GlobeNewswire
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS for coverage for the trialDebt facility amended to extend maturity date to 2031 and to increase the facility from the $50 million of term loans already drawn by an additional $50 million, of which $10 million was funded at closing MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, to
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. InvestorsGlobeNewswire
- CVRx Announces Implementation of New Category I CPT Codes for Barostim TherapyGlobeNewswire
- CVRx (NASDAQ:CVRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- CVRx to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- CVRx to Participate at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
CVRX
Earnings
- 11/5/25 - Beat
CVRX
Sec Filings
- 1/12/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- 1/12/26 - Form 424B5
- CVRX's page on the SEC website